Dr. Alan Chang

Dr. Alan Chang has about 20+ years of biopharma experience working at multinational companies. Alan's PhD was focused on particle engineering, formulation, and new emerging technologies for production. While at Nektar therapeutics, he improved its process and clinical production on a diabetic product that was done in collaboration with Pfizer. During his decade long stint with Novartis he led formulation and process development on many early to late-stage drug products. He worked with many functional groups and successfully moved several products to clinical production as well as help move one of Novartis project pass PAI and into commercial production. He has many years of experience dealing with drug regulatory audits and inspections with US FDA, EMA, NMPA, and many more. Alan was Director of Science and Operations for Ipharma, an inhalation CRO start up in San Francisco and Hong Kong, and was recently acquired by 3M's spinoff, Kindeva. He is the co-founder and CEO of Taron Solutions, Hong Kong's only biologics CDMO with the mission of helping drug development companies complete their pre-IND/development phase right the first time so that they can move towards large scale GMP production smoothly. Taron currently teamed up with University of Hong Kong's CVVT (Centre for Virology, Vaccine and Therapeutics), led by Prof. Yuen Kwok Yung and Prof. Chen Hong Lin, to help build a biologic vaccine plant and help commercialize an intranasal vaccine product in Hong Kong to ensure regional biosecurity.